SCHEMBL3520739

SCHEMBL3520739

COC(=O)c1c(OC)c(-c2ccccc2)cc2ncc(-c3ccccc3)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 2/20 0.46
GLA P06280 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
GABRA1 P14867 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
HTT P42858 1/20 0.42
PLA2G2A P14555 1/20 0.42
JAK2 O60674 2/20 0.41
JAK1 P23458 2/20 0.41
TYK2 P29597 2/20 0.41
JAK3 P52333 2/20 0.41
PARP1 P09874 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3516674 0.91 SMN1; SMN2 (0.46) SMN1; SMN2GAAMAPTALDH1A1GLA
SCHEMBL3518631 0.87 SMN1; SMN2 (0.45) SMN1; SMN2GAAMAPTALDH1A1GLA
SCHEMBL3517714 0.81 ALDH1A1 (0.42) SMN1; SMN2GAAMAPTALDH1A1GLA
SCHEMBL3524365 0.80 MEN1 (0.48) SMN1; SMN2GAAMAPTALDH1A1GLA
SCHEMBL3753086 0.80 SMN1; SMN2 (0.52) SMN1; SMN2GAAMAPTALDH1A1GLA
SCHEMBL4115260 0.77 HTT (0.54) GAAMAPTALDH1A1GABRA1GABRG2
SCHEMBL3758623 0.76 NPC1 (0.41) SMN1; SMN2MAPTALDH1A1NPC1RAB9A
SCHEMBL3518924 0.76 RPS6KB1 (0.41) GABRA5PLA2G2APDGFRB
SCHEMBL3520359 0.75 EGLN3 (0.44) SMN1; SMN2GAAMAPTALDH1A1GLA
SCHEMBL3520500 0.73 PDGFRB (0.40) RAB9APLA2G2APDGFRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 SMN1; SMN2 3777/4885GAA 142/4885MAPT 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.